Literature DB >> 26131280

HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression.

Ping He1, Jiexiong Liang1, Tiansong Shao1, Yang Guo1, Yingchen Hou1, Yang Li1.   

Abstract

The histone deacetylase (HDACs) family contains a family of enzymes, which are involved in modulating a wide range of cellular processes, such as proliferation, differentiation, apoptosis, and cell cycle progression. However, the biological function of HDAC5 in colorectal cancer has not been well established. In the current research, our data showed that the mRNA and protein levels of HDAC5 were up-regulated in human colorectal cancer cell lines. CCK-8 assay showed that overexpression of HDAC5 significantly promoted the proliferation of colorectal cancer cell lines including SW480 and HCT116. On the contrary, HDAC5 knockdown using small interfering RNA suppressed cell growth in colorectal tumor cells. At the molecular level, we demonstrated that HDAC5 promoted the expression of DLL4. In addition, down-regulation of DLL4 diminished the proliferative effects of HDAC5 in human colorectal cancer cells. Taken together, these results suggest that HDAC5 elevates the proliferation of colorectal cancer cells through up-regulation of DLL4. The current study might provide novel potential therapeutic targets in the treatment of colorectal cancer.

Entities:  

Keywords:  Colorectal cancer; DLL4; HDAC5; proliferation

Year:  2015        PMID: 26131280      PMCID: PMC4483821     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Vania Gelmetti; Francesco Marchesi; Andrea Viale; Lucia Altucci; Clara Nervi; Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

2.  Receptor-independent protein kinase C alpha (PKCalpha) signaling by calpain-generated free catalytic domains induces HDAC5 nuclear export and regulates cardiac transcription.

Authors:  Yan Zhang; Scot J Matkovich; Xiujun Duan; Abhinav Diwan; Min-Young Kang; Gerald W Dorn
Journal:  J Biol Chem       Date:  2011-06-03       Impact factor: 5.157

Review 3.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

4.  Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.

Authors:  Marinus R Heideman; Roel H Wilting; Eva Yanover; Arno Velds; Johann de Jong; Ron M Kerkhoven; Heinz Jacobs; Lodewyk F Wessels; Jan-Hermen Dannenberg
Journal:  Blood       Date:  2013-01-17       Impact factor: 22.113

5.  Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.

Authors:  Linda Marek; Alexandra Hamacher; Finn K Hansen; Krystina Kuna; Holger Gohlke; Matthias U Kassack; Thomas Kurz
Journal:  J Med Chem       Date:  2013-01-08       Impact factor: 7.446

6.  Mesenchymal stem cells modified with miR-126 release angiogenic factors and activate Notch ligand Delta-like-4, enhancing ischemic angiogenesis and cell survival.

Authors:  Feng Huang; Xiao Zhu; Xin-Qun Hu; Zhen-Fei Fang; Liang Tang; Xiao-Ling Lu; Sheng-Hua Zhou
Journal:  Int J Mol Med       Date:  2012-12-03       Impact factor: 4.101

Review 7.  [Histone deacetylases: a new class of efficient anti-tumor drugs].

Authors:  Denis Mottet; Vincent Castronovo
Journal:  Med Sci (Paris)       Date:  2008 Aug-Sep       Impact factor: 0.818

8.  An impending cancer crisis in developing countries: are we ready for the challenge?

Authors:  Mahmood Ur Rehman; Qasim M Buttar; Mohammad Irfan-ul-Haq Khawaja; Muhammad Rizwan-ul-Haq Khawaja
Journal:  Asian Pac J Cancer Prev       Date:  2009 Oct-Dec

Review 9.  Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.

Authors:  Fritz Lai; Lei Jin; Stuart Gallagher; Branka Mijatov; Xu Dong Zhang; Peter Hersey
Journal:  Adv Pharmacol       Date:  2012

Review 10.  Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Authors:  Zhiming Li; Wei-Guo Zhu
Journal:  Int J Biol Sci       Date:  2014-07-02       Impact factor: 6.580

View more
  12 in total

1.  Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition.

Authors:  E Hendrick; P Peixoto; A Blomme; C Polese; N Matheus; J Cimino; A Frère; A Mouithys-Mickalad; D Serteyn; L Bettendorff; B Elmoualij; P De Tullio; G Eppe; F Dequiedt; V Castronovo; D Mottet
Journal:  Oncogene       Date:  2017-04-17       Impact factor: 9.867

2.  High HDAC5 expression correlates with a poor prognosis and the tumor immune microenvironment in gastric cancer.

Authors:  Li Yuan; Can Hu; Pengcheng Yu; Zhehan Bao; Yuhang Xia; Bo Zhang; Yi Wang
Journal:  Ann Transl Med       Date:  2022-09

3.  HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.

Authors:  Chunyu Cao; Hao Wu; Shauna N Vasilatos; Uma Chandran; Ye Qin; Yong Wan; Steffi Oesterreich; Nancy E Davidson; Yi Huang
Journal:  Int J Cancer       Date:  2018-04-20       Impact factor: 7.396

Review 4.  The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair.

Authors:  Wynand Paul Roos; Andrea Krumm
Journal:  Nucleic Acids Res       Date:  2016-10-13       Impact factor: 16.971

5.  Opposite effects of HDAC5 and p300 on MRTF-A-related neuronal apoptosis during ischemia/reperfusion injury in rats.

Authors:  Na Li; Qiong Yuan; Xiao-Lu Cao; Ying Zhang; Zhen-Li Min; Shi-Qiang Xu; Zhi-Jun Yu; Jing Cheng; Chunxiang Zhang; Xia-Min Hu
Journal:  Cell Death Dis       Date:  2017-02-23       Impact factor: 8.469

6.  TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.

Authors:  Jun-Chuang He; Wei Yao; Jian-Ming Wang; Peter Schemmer; Yan Yang; Yan Liu; Ya-Wei Qian; Wei-Peng Qi; Jian Zhang; Qi Shen; Tao Yang
Journal:  Oncotarget       Date:  2016-11-15

7.  Therapeutic strategies against cancer stem cells in human colorectal cancer.

Authors:  Magdalena Szaryńska; Agata Olejniczak; Jarosław Kobiela; Piotr Spychalski; Zbigniew Kmieć
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

Review 8.  Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.

Authors:  Jun Yang; Chaoju Gong; Qinjian Ke; Zejun Fang; Xiaowen Chen; Ming Ye; Xi Xu
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

9.  miR-30 Family Controls Proliferation and Differentiation of Intestinal Epithelial Cell Models by Directing a Broad Gene Expression Program That Includes SOX9 and the Ubiquitin Ligase Pathway.

Authors:  Bailey C E Peck; John Sincavage; Sydney Feinstein; Amanda T Mah; James G Simmons; P Kay Lund; Praveen Sethupathy
Journal:  J Biol Chem       Date:  2016-06-03       Impact factor: 5.157

10.  Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.

Authors:  C Cao; S N Vasilatos; R Bhargava; J L Fine; S Oesterreich; N E Davidson; Y Huang
Journal:  Oncogene       Date:  2016-05-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.